Related Experiment Video

Updated: Jun 6, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Targeting HER2 in breast cancer: overview of long-term experience

Evan Lantz1, Ivan Cunningham, Gerald M Higa

  • 1School of Pharmacy.

International Journal of Women'S Health
|November 13, 2010
PubMed

Insights

Researchers explore the HER2 oncogene

Area of Science:

  • Genomics in oncology
  • Molecular biology of cancer

Background:

  • Genomic insights have advanced breast cancer understanding and treatment.
  • The HER2 oncogene, when overexpressed, promotes breast tumor cell growth and survival.

Purpose of the Study:

  • To provide a historical and current perspective on treating HER2-positive breast cancer.
  • To review the development and impact of therapies targeting the HER2 receptor.

Main Methods:

  • Review of historical and current clinical trial data.
  • Analysis of genomic findings related to the HER2 oncogene.
  • Examination of therapeutic strategies targeting HER2-positive breast tumors.

Main Results:

  • Overexpression of the HER2 receptor confers growth and survival advantages.
  • Targeted therapies inhibiting HER2 signaling have improved outcomes in HER2-positive breast cancer.
  • Challenges remain, including non-response and relapse after initial treatment.

Conclusions:

  • Therapies targeting HER2 have significantly impacted HER2-positive breast cancer treatment.
  • Ongoing research is crucial to address treatment resistance and improve patient outcomes.
Keywords:
ErbBHER2adjuvant therapylapatinibmetastatic breast cancerneo-adjuvant therapy

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...